Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday…
Through 6 distinctive sessions, the WSC Spotlight will give an overview of the global epidemiology and burden of sepsis and AMR, exploring innovative, novel, and cost-effective approaches for the prevention…
Authors: Bollen PDJ, Moore C, Mujuru H, et al. The ODYSSEY Trial Team Published in: LANCET HIV. 2020;8:e533-e544 Date of publication: 20 August 2020 Download publication
Last Patient Last Visit (LPLV) completed for the Penta 17 Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (SMILE) trial.
Results from from the ongoing P1093 and ODYSSEY (PENTA20) studies, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of…
A correspondence by Malte Kohns at St George’s University London to The Lancet Infectious Disease Journal, focusing on the importance of international collaboration.
Paolo Palma and his colleagues recently published in The Lancet HIV the paper “The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV”
EPPICC was awarded a grant from the ViiV Global HIV and COVID-19 Emergency Fund to conduct research on the direct and indirect impact of COVID-19 on children and adolescents living…
Our collaborator Prof. Mike Sharland, together with GARDP and St. George’s, University of London researchers have just published a new paper in the WHO Bulletin investigating international antibiotic sales data…
Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation…
COVID-19, the new infectious disease which has uprooted our lives, social relationships and work habits, has turned out to be an unmissable opportunity to rethink our collaborative research and strive to drive attention…
COVID-19, the new infectious disease which has uprooted our lives, social relationships and work habits, has turned out to be an unmissable opportunity to rethink our collaborative research and strive to drive attention…